OLMA Key Statistics, Chart & Performance
The current stock price of OLMA is 23.17 USD. In the past month the price increased by 188.54%. In the past year, price increased by 163.9%.
OLMA Latest News, Press Relases and Analysis
OLMA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 25 | 417.40B | ||
| AMGN | AMGEN INC | 15.43 | 181.72B | ||
| GILD | GILEAD SCIENCES INC | 15.46 | 157.14B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.58 | 109.42B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.79 | 80.12B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 855.65 | 57.20B | ||
| INSM | INSMED INC | N/A | 42.01B | ||
| NTRA | NATERA INC | N/A | 31.65B | ||
| BIIB | BIOGEN INC | 10.47 | 25.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.99 | 21.48B | ||
| INCY | INCYTE CORP | 15.9 | 19.93B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.10B |
Related stock screener links
About OLMA
Company Profile
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of next generation targeted therapies for women’s cancers. The company is headquartered in San Francisco, California and currently employs 116 full-time employees. The company went IPO on 2020-11-19. The firm is focused on transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. The company is advancing a pipeline of novel therapies by leveraging its deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Its lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), in a Phase 3 clinical trial called OPERA-01. The company is being investigated in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. In addition, it is developing OP-3136, a potent KAT6 inhibitor, in a Phase 1 clinical trial. OP-3136 is a novel, orally available small molecule that potently and selectively inhibits KAT6.
Company Info
OLEMA PHARMACEUTICALS INC
780 Brannan Street
San Francisco CALIFORNIA 94107 US
CEO: Sean Bohen
Employees: 116
Phone: 14156513316
OLEMA PHARMACEUTICALS INC / OLMA FAQ
What does OLEMA PHARMACEUTICALS INC do?
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of next generation targeted therapies for women’s cancers. The company is headquartered in San Francisco, California and currently employs 116 full-time employees. The company went IPO on 2020-11-19. The firm is focused on transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. The company is advancing a pipeline of novel therapies by leveraging its deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Its lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), in a Phase 3 clinical trial called OPERA-01. The company is being investigated in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. In addition, it is developing OP-3136, a potent KAT6 inhibitor, in a Phase 1 clinical trial. OP-3136 is a novel, orally available small molecule that potently and selectively inhibits KAT6.
Can you provide the latest stock price for OLEMA PHARMACEUTICALS INC?
The current stock price of OLMA is 23.17 USD. The price increased by 5.27% in the last trading session.
Does OLEMA PHARMACEUTICALS INC pay dividends?
OLMA does not pay a dividend.
What is the ChartMill rating of OLEMA PHARMACEUTICALS INC stock?
OLMA has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the valuation of OLEMA PHARMACEUTICALS INC (OLMA) based on its PE ratio?
OLEMA PHARMACEUTICALS INC (OLMA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.87).
Can you provide the market cap for OLEMA PHARMACEUTICALS INC?
OLEMA PHARMACEUTICALS INC (OLMA) has a market capitalization of 1.59B USD. This makes OLMA a Small Cap stock.
What is the Short Interest ratio of OLEMA PHARMACEUTICALS INC (OLMA) stock?
The outstanding short interest for OLEMA PHARMACEUTICALS INC (OLMA) is 12.72% of its float.
OLMA Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to OLMA. When comparing the yearly performance of all stocks, OLMA is one of the better performing stocks in the market, outperforming 99.29% of all stocks.
OLMA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to OLMA. While OLMA seems to be doing ok healthwise, there are quite some concerns on its profitability.
OLMA Financial Highlights
Over the last trailing twelve months OLMA reported a non-GAAP Earnings per Share(EPS) of -1.87. The EPS increased by 14.61% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -37.25% | ||
| ROE | -41.22% | ||
| Debt/Equity | 0.01 |
OLMA Forecast & Estimates
15 analysts have analysed OLMA and the average price target is 24.19 USD. This implies a price increase of 4.4% is expected in the next year compared to the current price of 23.17.